Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as ...

Palisade Bio's PALI-2108 could be a game-changer for gut health with strong upside potential. Read here for an investment analysis of PALI stock.

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...

Palisade Bio (PALI) announced that the Japan Patent Office has granted a key patent covering PALI-2108, the Company’s lead, ...

Fintel reports that on December 30, 2025, Clear Street initiated coverage of Palisade Bio (NasdaqCM:PALI) with a Buy recommendation. Analyst Price Forecast Suggests 405.31% Upside As of December 21, ...

NUUANU (KHNL) -- We've all heard of those chilling tales of Hawaiian folklore. And two very specific ones always seemed to make the hair on the back of my neck stand, whenever I heard them. One, was ...